PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer
- 1 December 2000
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 21 (12), 469-474
- https://doi.org/10.1016/s0165-6147(00)01559-5
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptors: Nuclear Control of MetabolismEndocrine Reviews, 1999
- PPARγ-Ligands Inhibit Migration Mediated by Multiple Chemoattractants in Vascular Smooth Muscle CellsJournal of Cardiovascular Pharmacology, 1999
- Peroxisome Proliferator‐activated Receptor γ Induces Growth Arrest and Differentiation Markers of Human Colon Cancer CellsJapanese Journal of Cancer Research, 1999
- Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte DifferentiationThe New England Journal of Medicine, 1998
- Treatment of Psoriasis With Troglitazone TherapyArchives of Dermatology, 1998
- Troglitazone Effects on Gene Expression in Human Skeletal Muscle of Type II Diabetes Involve Up-Regulation of Peroxisome Proliferator-Activated Receptor-Journal of Clinical Endocrinology & Metabolism, 1998
- Subtype- and response element-dependent differences in transactivation by peroxisome proliferator-activated receptors α and γMolecular and Cellular Endocrinology, 1998
- Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγCell, 1998
- Troglitazone action is independent of adipose tissue.JCI Insight, 1997
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993